Centuple Global

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE396H01019
  • NSEID:
  • BSEID: 531099
INR
32.30
-1.69 (-4.97%)
BSENSE

Nov 20

BSE+NSE Vol: 502

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 510537,
    "name": "Centuple Global",
    "stock_name": "Centuple Global",
    "full_name": "Centuple Global Ltd",
    "name_url": "stocks-analysis/centuple-global",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "32.30",
    "chg": -1.69,
    "chgp": "-4.97%",
    "dir": -1,
    "prev_price": "33.99",
    "mcapval": "19.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531099,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE396H01019",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "502 ",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/centuple-global-510537-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Centuple Global Ltd Falls 4.75%: 2 Key Factors Behind the Weekly Decline",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/centuple-global-ltd-falls-475-2-key-factors-behind-the-weekly-decline-4270800",
        "imagepath": "",
        "date": "2026-11-21 17:04:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Nov:</strong> Stock opens at Rs.32.62, down 3.80% amid downgrade news</p>\n                    <p><strong>17 Nov:</strong> Upgrade in valuation grade to Attractive; price rises 4.84% to Rs.34.20</p>\n                    <p><strong>18 Nov:</strong> Price retreats 4.53% to Rs.32.65 following sector challenges</p>\n                    <p><strong>19 Nov:</strong> Strong volume surge; price rebounds 4.10% to Rs.33.99</p>\n                    <p><strong>20 Nov:</strong> Week closes lower at Rs.32.30, down 4.97% on moderate volume</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class..."
      },
      {
        "title": "Centuple Global Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/centuple-global-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-4265960",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/CentupleGlobalL_valuationdot_4265960.png",
        "date": "2026-11-18 08:02:44",
        "description": "Centuple Global Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters improve from very attractive to attractive, signalling a potential shift in price attractiveness despite ongoing challenges in its financial performance and market returns."
      },
      {
        "title": "Centuple Global Ltd Downgraded to Strong Sell Amid Flat Financials and Weak Fundamentals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/centuple-global-ltd-downgraded-to-strong-sell-amid-flat-financials-and-weak-fundamentals-4264779",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/CentupleGlobalL_mojoScore_4264779.png",
        "date": "2026-11-17 08:30:10",
        "description": "Centuple Global Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its quality, valuation, financial trend, and technical parameters. The downgrade reflects a combination of flat recent financial performance, deteriorating fundamentals, and subdued market momentum, signalling caution for investors amid challenging conditions."
      },
      {
        "title": "Centuple Global Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/centuple-global-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-4213598",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/CentupleGlobalL_valuationdot_4213598.png",
        "date": "2026-10-05 08:01:29",
        "description": "Centuple Global Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite a challenging year marked by significant share price declines and underperformance relative to the Sensex, the company’s improved price-to-earnings and price-to-book ratios suggest a potential revaluation opportunity for investors willing to navigate sector headwinds."
      },
      {
        "title": "Centuple Global Ltd Falls 14.54%: 4 Key Factors Driving the Sharp Decline",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/centuple-global-ltd-falls-1454-4-key-factors-driving-the-sharp-decline-4198467",
        "imagepath": "",
        "date": "2026-09-19 17:02:29",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>15 Sep:</strong> Stock opens at Rs.34.87, down 0.37% amid broader market weakness</p>\n                    <p><strong>16 Sep:</strong> Valuation shifts signal changing market perception; stock drops 4.99%</p>\n                    <p><strong>17 Sep:</strong> Falls to 52-week low of Rs.31.48, down 4.98%</p>\n                    <p><strong>18 Sep:</strong> Downgraded to Strong Sell; hits new 52-week low of Rs.29.91</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.35.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</di..."
      },
      {
        "title": "Five Consecutive Losses Push Centuple Global Ltd to a New 52-Week Low",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/centuple-global-ltd-falls-to-52-week-low-amidst-continued-downtrend-4196975",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/CentupleGlobalL_priceRelatedfactors_4196975.png",
        "date": "2026-09-18 09:43:37",
        "description": ""
      },
      {
        "title": "Centuple Global Ltd Downgraded to Strong Sell Amid Technical and Financial Concerns",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/centuple-global-ltd-downgraded-to-strong-sell-amid-technical-and-financial-concerns-4196845",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/CentupleGlobalL_mojoScore_4196845.png",
        "date": "2026-09-18 08:07:51",
        "description": "Centuple Global Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 17 September 2026. This shift reflects deteriorating technical indicators, modest valuation improvements, weak financial trends, and a challenging market environment that has weighed heavily on the stock’s performance."
      },
      {
        "title": "Centuple Global Ltd Falls to 52-Week Low of Rs 31.48 as Sell-Off Deepens",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/centuple-global-ltd-falls-to-52-week-low-amidst-continued-downtrend-4195927",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/CentupleGlobalL_priceRelatedfactors_4195927.png",
        "date": "2026-09-17 09:39:09",
        "description": "For the fourth consecutive session, Centuple Global Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 31.48 on 17 Sep 2026. This marks a 12.53% drop over the last four days, underscoring persistent selling pressure despite some positive financial indicators."
      },
      {
        "title": "Centuple Global Ltd Valuation Shifts Signal Changing Market Perception",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/centuple-global-ltd-valuation-shifts-signal-changing-market-perception-4193883",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/CentupleGlobalL_valuationdot_4193883.png",
        "date": "2026-09-16 08:00:41",
        "description": "Centuple Global Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. Despite a challenging market environment and significant underperformance relative to the Sensex, the company’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more compelling price entry point for investors seeking exposure to this segment."
      }
    ],
    "total": 24,
    "sid": "510537",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/centuple-global-510537"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "17-Nov-2026",
      "details": "Submission of Copy of Publiaction of Advertisement of Unaudited Standalone Financial Results.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Board Meeting Outcome For The Meeting Of The Board Of Directors",
      "datetime": "13-Nov-2026",
      "details": "Outcome of the Meeting of the Board of Directors for approval of Unaudited Standalone Financial Results",
      "source": "BSE"
    },
    {
      "caption": " Shareholder Meeting / Postal Ballot-Scrutinizer\"s Report",
      "datetime": "13-Nov-2026",
      "details": "Scrutinizer Report - Postal Ballot",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

17-Nov-2026 | Source : BSE

Submission of Copy of Publiaction of Advertisement of Unaudited Standalone Financial Results.

Board Meeting Outcome for Board Meeting Outcome For The Meeting Of The Board Of Directors

13-Nov-2026 | Source : BSE

Outcome of the Meeting of the Board of Directors for approval of Unaudited Standalone Financial Results

Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

13-Nov-2026 | Source : BSE

Scrutinizer Report - Postal Ballot

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available